The past, present and future of hypertension management: A potential role for AT1-receptor antagonists

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 1, 2000, Pages 5-10

  Hollenberg, Norman K ^a   Sever, Peter S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin receptor antagonists; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR;

ANIMAL; CARDIOLOGY; DRUG ANTAGONISM; EDITORIAL; HUMAN; HYPERTENSION;

ANIMALS; CARDIOLOGY; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN;

EID: 0034160527     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.011     Document Type: Review

References (54)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 212: 1028-1034.
2. Health Survey for England '96.Volume 1. London:The Stationery Office, 1998.
3. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee.The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
4. Dickinson CJ. Neurogenic hypertension: a synthesis and review. London: Chapman and Hall, 1991.
5. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-271.
6. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-1152.
7. Medical Research Council Working Party. MRC trial on treatment of hypertension: principal results. BMJ 1985; 291: 97-104.
8. Dahlöf B, Lindeholm LH, Hansson L et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1284.
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255-3264.
10. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.
11. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350: 757-764.
12. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients. New Engl J Med 2000; 342: 145-153.
13. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
14. Hansson L, Zanchetti A, Carruthers G et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
15. Taylor Nelson Healthcare: Copyright Cardiomonitor *, 1992.
16. Burt V-L, Wheiton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313.
17. Bennett SA, Magnus P. Trends in cardiovascular risk factors in Australia. Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980-1989. Med J Australia 1994; 161: 519-527.
18. Hosie J, Wiklund I. Managing hypertension in general practice: Can we do better? J Hum Hypertens 1995; 9: 515-518.
19. Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-156.
20. Jones JK, Gorkin L, Lian JF et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293-295.
21. Juilleret L, Nussberger J, Ménard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-572.
22. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 1996; 9: 277-284.
23. Ménard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 1997; 11(suppl 2):S1-7.
24. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
25. Sunman W, Sever PS. Non-angiotensin effects of angiotensin converting enzyme inhibitors. Clin Sci 1993; 85: 661-670.
26. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996; 28: 635-640.
27. 2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996; 94: 3087-3089.
28. 1-receptor antagonists on angiotesin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol 1999;127(8):1876-82.
29. 1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-1413.
30. 1-receptors. Br J Pharmacol 1999; 126: 1057-1065.
31. Chiu AT, Mccall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, & Timmermans PB. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DUP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
32. Corriu C, Bernard S, Schott C & Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995; 26: 688-692.
33. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T & Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46: 311-318.
34. Chiu AT, Mccall D., Aldrich PE & Timmermans PB. [3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Commun 1990; 172: 1195-202.
35. Chiu AT, Mccall DE, Ardecky RJ, Duncia JV, Nguyen TT & Timmermans PB. Angiotensin II receptor subtypes and their selective nonpeptide ligands. Receptor 1990; 1: 33-40.
36. Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD & Timmermans PB. Functional studies of nonpeptidc angiotensin II receptor subtype-specific ligands: DUP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990; 255: 584-592.
37. 1-receptor. Eur J Pharmacol 1997; 319: 137-146.
38. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure 1998; 7: 53-59.
39. Kassler-Taub K, Littlejohn T, Elliott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11(4, part 1):445-453.
40. Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
41. Lacourcière Y, Asmar R, on behalf of the CHAMP study group. Comparison of the impact of missed doses of candesartan and losartan in ambulatory hypertensive patients. Am J Hypertens 1999; 12(4, part 2): 143A.
42. Inada Y, Wada T, Ojima M et al. Protective effects of candesartan cilexetil (TCV116) on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19: 1079-1099.
43. 1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 469-474.
44. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998; 16: S23-S29.
45. Tedesco MA, Ratti G, Aquino D et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12: 505-510.
46. Thurmann PA, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
47. Fridman K, Andersson OK, Wysocki M, Friberg P. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998; 54: 497-501.
48. Fridman K, Wysocki M, Friberg P, Andersson O. Long term effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients. Am J Hypertens 1998; 11(4, part 2): 77A.
49. Forsblom C, Trenkwalder P, Dahl K et al. Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension. Am J Hypertens 1997; 10(4, part 2): 86A.
50. Dahlöf B, Devereux RB, Julius S et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. Hypertension 1998; 32: 989-997.
51. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998; 7: 176-183.
52. Hansson L, Lithell H, Skoog I et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure 1999; 8: 177-183.
53. 1-receptor antagonists: clinical development and future perspectives. J Therapie 1998; 53: 279-284. (French).
54. Ritz E, Rychlik I, Miltenberger-Miltenyi G. Optimizing antihypertensive therapy in patients with diabetic nephropathy. J Hypertens Suppl 1998; 16(7):S17-S22.